Shan Yu

2.3k total citations
61 papers, 1.0k citations indexed

About

Shan Yu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Shan Yu has authored 61 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 21 papers in Pulmonary and Respiratory Medicine and 21 papers in Oncology. Recurrent topics in Shan Yu's work include Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Shan Yu is often cited by papers focused on Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Shan Yu collaborates with scholars based in China, United States and Hong Kong. Shan Yu's co-authors include Tianshu Liu, Yiyi Yu, Yuehong Cui, Ke Peng, Naiqing Zhao, Cheng Tang, Wěi Li, Qian Li, Erbao Chen and Jianlan Cui and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Shan Yu

59 papers receiving 1.0k citations

Peers

Shan Yu
Hui Sheng China
Panagiotis Sarantis Greece
Ning Liu China
Yoshifumi Nakayama Japan
Jinghai Song China
Xiang Gao China
Fangxuan Li China
Rainer Hamacher Germany
Hui Sheng China
Shan Yu
Citations per year, relative to Shan Yu Shan Yu (= 1×) peers Hui Sheng

Countries citing papers authored by Shan Yu

Since Specialization
Citations

This map shows the geographic impact of Shan Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shan Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shan Yu more than expected).

Fields of papers citing papers by Shan Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shan Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shan Yu. The network helps show where Shan Yu may publish in the future.

Co-authorship network of co-authors of Shan Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Shan Yu. A scholar is included among the top collaborators of Shan Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shan Yu. Shan Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Guan, Bin, Lingyun Zhang, & Shan Yu. (2024). Acute coronary syndrome in a patient with gastric cancer treated by immune checkpoint inhibitor: A case report. 1(2). 136–140. 1 indexed citations
3.
Dong, Shuyan, Ming Zhao, Jin Zhu, et al.. (2024). Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma. Frontiers in Immunology. 15. 1442673–1442673. 4 indexed citations
4.
Wu, Dehai, Guanqun Liao, Liang Ming, et al.. (2024). Identified a novel prognostic model of HCC basing on virus signature for guiding immunotherapy. Discover Oncology. 15(1). 551–551. 1 indexed citations
5.
Xu, Xiaojing, Luoyan Ai, Li Liang, et al.. (2024). Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nature Communications. 15(1). 7255–7255. 16 indexed citations
6.
Xu, Xiaojing, Yiyi Yu, Yuehong Cui, et al.. (2023). Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.. Journal of Clinical Oncology. 41(4_suppl). 125–125. 1 indexed citations
7.
8.
Wu, Yingnan, et al.. (2022). LncmiRHG-MIR100HG: A new budding star in cancer. Frontiers in Oncology. 12. 997532–997532. 14 indexed citations
9.
Li, Ting, et al.. (2022). Exosomes: Potential Biomarkers and Functions in Head and Neck Squamous Cell Carcinoma. Frontiers in Molecular Biosciences. 9. 881794–881794. 9 indexed citations
10.
Liu, Qing, Yiyi Yu, Jinyi Lin, et al.. (2021). Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. European Journal of Cancer. 157. 10–20. 8 indexed citations
11.
Yu, Shan, Qian Li, Yan Wang, et al.. (2021). Tumor-derived LIF promotes chemoresistance via activating tumor-associated macrophages in gastric cancers. Experimental Cell Research. 406(1). 112734–112734. 13 indexed citations
12.
Yu, Shan, Qian Li, Yiyi Yu, et al.. (2020). Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer. Cancer Immunology Immunotherapy. 69(10). 1973–1987. 38 indexed citations
13.
Yu, Shan, Yan Wang, Minzhi Lv, et al.. (2020). <p>Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients</p>. Cancer Management and Research. Volume 12. 10091–10101. 4 indexed citations
14.
Zhang, Qingyu, et al.. (2019). FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer. Journal of Cellular and Molecular Medicine. 23(7). 4569–4581. 15 indexed citations
15.
16.
Yu, Shan, Yan Wang, Yuehong Cui, et al.. (2018). The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer. 22(3). 587–597. 18 indexed citations
17.
Jiang, Huiqin, Quan‐Lin Li, Shan Yu, et al.. (2016). Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis. Clinical & Translational Oncology. 19(2). 197–203. 9 indexed citations
18.
Liu, Mi‐Hua, Xiao‐Long Lin, Cong Yuan, et al.. (2015). Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting the expression of peroxiredoxin III in H9c2 cells. Molecular Medicine Reports. 13(1). 367–372. 5 indexed citations
19.
Liu, Xishi, Shan Yu, & Sun‐Wei Guo. (2014). A pilot study on the use of andrographolide to treat symptomatic adenomyosis. Gynecology and Minimally Invasive Therapy. 3(4). 119–126. 15 indexed citations
20.
Liu, Qian, Li Zhang, Kun Wang, et al.. (2013). Effects of glucose and insulin on the H9c2 (2-1) cell proliferation may be mediated through regulating glucose transporter 4 expression. Chinese Medical Journal. 126(21). 4037–4042. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hui Sheng Breakdown of academic impact, for papers by Panagiotis Sarantis Breakdown of academic impact, for papers by Ning Liu Breakdown of academic impact, for papers by Yoshifumi Nakayama Breakdown of academic impact, for papers by Jinghai Song Breakdown of academic impact, for papers by Xiang Gao Breakdown of academic impact, for papers by Fangxuan Li Breakdown of academic impact, for papers by Rainer Hamacher
Rankless by CCL
2026